Blinatumomab Biosimilar – Research Grade [ICH5025]

ichorbio’s blinatumomab biosimilar is for Research Use Only (RUO) and not for therapeutic use.

CD19/CD3

Bispecific

MT103

CHO cells

Human

Detects human CD19/CD3. This non-therapeutic antibody uses the same sequence as blinatumomab.

This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Blinatumomab is a bispecific T-cell engager (BiTE). It enables a patient’s T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.

1.0 – 5.0 mg/ml

Sterile, preservative-free, solution in PBS. BSA and Azide free.

>95% by SDS-PAGE and HPLC

≤ 1.0 EU/mg as determined by the LAL method

Blinatumomab biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Functional Assays

Each investigator should determine their own optimal working dilution for specific applications.